An Open-label, Randomised, Placebo Controlled, Two-Way Crossover, Phase I Single Centre Study in Type 2 Diabetes Mellitus Patients Treated With Metformin to Evaluate the Pharmacokinetics of Digoxin During Co-administration With AZD1656.
Phase of Trial: Phase I
Latest Information Update: 09 Dec 2010
At a glance
- Drugs AZD 1656; Digoxin
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 09 Dec 2010 Planned End Date changed from 1 Nov 2010 to 1 Dec 2010 as reported by ClinicalTrials.gov.
- 27 Sep 2010 Additional location [USA] identified as reported by ClinicalTrials.gov.
- 27 Sep 2010 Planned end date changed from 1 Jul 2010 to 1 Nov 2010 as reported by ClinicalTrials.gov.